img

Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Research Report 2024

Idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis, IPF) is a rare, chronic, and fatal disease that will gradually develop over a period of several years. It is typically characterized by the formation of scar tissue in the lungs and progressive dyspnea. It is the most common type of interstitial lung disease in idiopathic interstitial pneumonia. Its clinical features include shortness of breath, diffuse lung infiltrates on imaging, and lung biopsy showing varying degrees of inflammation/fibrosis or Both.
According to Mr Accuracy reports’s new survey, global Idiopathic Pulmonary Fibrosis Disease Treatment market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Idiopathic Pulmonary Fibrosis Disease Treatment market research.
Key companies engaged in the Idiopathic Pulmonary Fibrosis Disease Treatment industry include Boehringer Ingelheim, Merck and Co., Inc., ArkBio, Zelgen, Blade Therapeutics, Regend Therapeutics (Cayman) Ltd., Insilico Medicine, Vicore Pharma and Heilongjiang Zbd Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Idiopathic Pulmonary Fibrosis Disease Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Idiopathic Pulmonary Fibrosis Disease Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Idiopathic Pulmonary Fibrosis Disease Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Boehringer Ingelheim
Merck and Co., Inc.
ArkBio
Zelgen
Blade Therapeutics
Regend Therapeutics (Cayman) Ltd.
Insilico Medicine
Vicore Pharma
Heilongjiang Zbd Pharmaceutical
Indaco
InterMune, Inc.
Bristol Myers Squibb
SHIONOGI & CO., Ltd.
Segment by Type
Pirfenidone
Nintedanib
Other

Segment by Application


Hospital
Graduate School
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Idiopathic Pulmonary Fibrosis Disease Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 Pirfenidone
1.2.3 Nintedanib
1.2.4 Other
1.3 Market by Application
1.3.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Graduate School
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Perspective (2024-2034)
2.2 Idiopathic Pulmonary Fibrosis Disease Treatment Growth Trends by Region
2.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size by Region (2024-2024)
2.2.3 Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Region (2024-2034)
2.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Dynamics
2.3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends
2.3.2 Idiopathic Pulmonary Fibrosis Disease Treatment Market Drivers
2.3.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Challenges
2.3.4 Idiopathic Pulmonary Fibrosis Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Pulmonary Fibrosis Disease Treatment Players by Revenue
3.1.1 Global Top Idiopathic Pulmonary Fibrosis Disease Treatment Players by Revenue (2024-2024)
3.1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Players (2024-2024)
3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue
3.4 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Concentration Ratio
3.4.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue in 2022
3.5 Idiopathic Pulmonary Fibrosis Disease Treatment Key Players Head office and Area Served
3.6 Key Players Idiopathic Pulmonary Fibrosis Disease Treatment Product Solution and Service
3.7 Date of Enter into Idiopathic Pulmonary Fibrosis Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Pulmonary Fibrosis Disease Treatment Breakdown Data by Type
4.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size by Type (2024-2024)
4.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Type (2024-2034)
5 Idiopathic Pulmonary Fibrosis Disease Treatment Breakdown Data by Application
5.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size by Application (2024-2024)
5.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2024-2034)
6.2 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024)
6.4 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2024-2034)
7.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024)
7.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2024-2034)
8.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2024-2024)
8.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2024-2034)
9.2 Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024)
9.4 Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2024-2034)
10.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024)
10.4 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Detail
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.1.4 Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.1.5 Boehringer Ingelheim Recent Development
11.2 Merck and Co., Inc.
11.2.1 Merck and Co., Inc. Company Detail
11.2.2 Merck and Co., Inc. Business Overview
11.2.3 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.2.4 Merck and Co., Inc. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.2.5 Merck and Co., Inc. Recent Development
11.3 ArkBio
11.3.1 ArkBio Company Detail
11.3.2 ArkBio Business Overview
11.3.3 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.3.4 ArkBio Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.3.5 ArkBio Recent Development
11.4 Zelgen
11.4.1 Zelgen Company Detail
11.4.2 Zelgen Business Overview
11.4.3 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.4.4 Zelgen Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.4.5 Zelgen Recent Development
11.5 Blade Therapeutics
11.5.1 Blade Therapeutics Company Detail
11.5.2 Blade Therapeutics Business Overview
11.5.3 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.5.4 Blade Therapeutics Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.5.5 Blade Therapeutics Recent Development
11.6 Regend Therapeutics (Cayman) Ltd.
11.6.1 Regend Therapeutics (Cayman) Ltd. Company Detail
11.6.2 Regend Therapeutics (Cayman) Ltd. Business Overview
11.6.3 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.6.4 Regend Therapeutics (Cayman) Ltd. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.6.5 Regend Therapeutics (Cayman) Ltd. Recent Development
11.7 Insilico Medicine
11.7.1 Insilico Medicine Company Detail
11.7.2 Insilico Medicine Business Overview
11.7.3 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.7.4 Insilico Medicine Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.7.5 Insilico Medicine Recent Development
11.8 Vicore Pharma
11.8.1 Vicore Pharma Company Detail
11.8.2 Vicore Pharma Business Overview
11.8.3 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.8.4 Vicore Pharma Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.8.5 Vicore Pharma Recent Development
11.9 Heilongjiang Zbd Pharmaceutical
11.9.1 Heilongjiang Zbd Pharmaceutical Company Detail
11.9.2 Heilongjiang Zbd Pharmaceutical Business Overview
11.9.3 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.9.4 Heilongjiang Zbd Pharmaceutical Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.9.5 Heilongjiang Zbd Pharmaceutical Recent Development
11.10 Indaco
11.10.1 Indaco Company Detail
11.10.2 Indaco Business Overview
11.10.3 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.10.4 Indaco Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.10.5 Indaco Recent Development
11.11 InterMune, Inc.
11.11.1 InterMune, Inc. Company Detail
11.11.2 InterMune, Inc. Business Overview
11.11.3 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.11.4 InterMune, Inc. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.11.5 InterMune, Inc. Recent Development
11.12 Bristol Myers Squibb
11.12.1 Bristol Myers Squibb Company Detail
11.12.2 Bristol Myers Squibb Business Overview
11.12.3 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.12.4 Bristol Myers Squibb Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.12.5 Bristol Myers Squibb Recent Development
11.13 SHIONOGI & CO., Ltd.
11.13.1 SHIONOGI & CO., Ltd. Company Detail
11.13.2 SHIONOGI & CO., Ltd. Business Overview
11.13.3 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Introduction
11.13.4 SHIONOGI & CO., Ltd. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
11.13.5 SHIONOGI & CO., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of Pirfenidone
Table 3. Key Players of Nintedanib
Table 4. Key Players of Other
Table 5. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 6. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 7. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2024-2024) & (US$ Million)
Table 8. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region (2024-2024)
Table 9. Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 10. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region (2024-2034)
Table 11. Idiopathic Pulmonary Fibrosis Disease Treatment Market Trends
Table 12. Idiopathic Pulmonary Fibrosis Disease Treatment Market Drivers
Table 13. Idiopathic Pulmonary Fibrosis Disease Treatment Market Challenges
Table 14. Idiopathic Pulmonary Fibrosis Disease Treatment Market Restraints
Table 15. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Players (2024-2024) & (US$ Million)
Table 16. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Players (2024-2024)
Table 17. Global Top Idiopathic Pulmonary Fibrosis Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment as of 2022)
Table 18. Ranking of Global Top Idiopathic Pulmonary Fibrosis Disease Treatment Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (CR5 and HHI) & (2024-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Idiopathic Pulmonary Fibrosis Disease Treatment Product Solution and Service
Table 22. Date of Enter into Idiopathic Pulmonary Fibrosis Disease Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2024-2024) & (US$ Million)
Table 25. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Type (2024-2024)
Table 26. Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 27. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Type (2024-2034)
Table 28. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2024-2024) & (US$ Million)
Table 29. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Application (2024-2024)
Table 30. Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 31. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Application (2024-2034)
Table 32. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 33. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 34. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 35. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 36. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 37. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 38. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 39. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2024-2024) & (US$ Million)
Table 40. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2024-2034) & (US$ Million)
Table 41. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 42. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 43. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 44. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 45. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 46. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 47. Boehringer Ingelheim Company Detail
Table 48. Boehringer Ingelheim Business Overview
Table 49. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 50. Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 51. Boehringer Ingelheim Recent Development
Table 52. Merck and Co., Inc. Company Detail
Table 53. Merck and Co., Inc. Business Overview
Table 54. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 55. Merck and Co., Inc. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 56. Merck and Co., Inc. Recent Development
Table 57. ArkBio Company Detail
Table 58. ArkBio Business Overview
Table 59. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 60. ArkBio Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 61. ArkBio Recent Development
Table 62. Zelgen Company Detail
Table 63. Zelgen Business Overview
Table 64. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 65. Zelgen Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 66. Zelgen Recent Development
Table 67. Blade Therapeutics Company Detail
Table 68. Blade Therapeutics Business Overview
Table 69. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 70. Blade Therapeutics Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 71. Blade Therapeutics Recent Development
Table 72. Regend Therapeutics (Cayman) Ltd. Company Detail
Table 73. Regend Therapeutics (Cayman) Ltd. Business Overview
Table 74. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 75. Regend Therapeutics (Cayman) Ltd. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 76. Regend Therapeutics (Cayman) Ltd. Recent Development
Table 77. Insilico Medicine Company Detail
Table 78. Insilico Medicine Business Overview
Table 79. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 80. Insilico Medicine Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 81. Insilico Medicine Recent Development
Table 82. Vicore Pharma Company Detail
Table 83. Vicore Pharma Business Overview
Table 84. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 85. Vicore Pharma Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 86. Vicore Pharma Recent Development
Table 87. Heilongjiang Zbd Pharmaceutical Company Detail
Table 88. Heilongjiang Zbd Pharmaceutical Business Overview
Table 89. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 90. Heilongjiang Zbd Pharmaceutical Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 91. Heilongjiang Zbd Pharmaceutical Recent Development
Table 92. Indaco Company Detail
Table 93. Indaco Business Overview
Table 94. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 95. Indaco Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 96. Indaco Recent Development
Table 97. InterMune, Inc. Company Detail
Table 98. InterMune, Inc. Business Overview
Table 99. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 100. InterMune, Inc. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 101. InterMune, Inc. Recent Development
Table 102. Bristol Myers Squibb Company Detail
Table 103. Bristol Myers Squibb Business Overview
Table 104. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 105. Bristol Myers Squibb Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 106. Bristol Myers Squibb Recent Development
Table 107. SHIONOGI & CO., Ltd. Company Detail
Table 108. SHIONOGI & CO., Ltd. Business Overview
Table 109. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product
Table 110. SHIONOGI & CO., Ltd. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024) & (US$ Million)
Table 111. SHIONOGI & CO., Ltd. Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Type: 2022 VS 2034
Figure 3. Pirfenidone Features
Figure 4. Nintedanib Features
Figure 5. Other Features
Figure 6. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Application: 2022 VS 2034
Figure 8. Hospital Case Studies
Figure 9. Graduate School Case Studies
Figure 10. Others Case Studies
Figure 11. Idiopathic Pulmonary Fibrosis Disease Treatment Report Years Considered
Figure 12. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 13. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 14. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region: 2022 VS 2034
Figure 15. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Players in 2022
Figure 16. Global Top Idiopathic Pulmonary Fibrosis Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue in 2022
Figure 18. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 19. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2024-2034)
Figure 20. United States Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 21. Canada Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 22. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 23. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2024-2034)
Figure 24. Germany Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 25. France Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 26. U.K. Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 27. Italy Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 28. Russia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. Nordic Countries Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 31. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region (2024-2034)
Figure 32. China Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 33. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 34. South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 35. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 36. India Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. Australia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 39. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2024-2034)
Figure 40. Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 41. Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 42. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 43. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2024-2034)
Figure 44. Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 45. Saudi Arabia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 46. Boehringer Ingelheim Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 47. Merck and Co., Inc. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 48. ArkBio Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 49. Zelgen Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 50. Blade Therapeutics Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 51. Regend Therapeutics (Cayman) Ltd. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 52. Insilico Medicine Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 53. Vicore Pharma Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 54. Heilongjiang Zbd Pharmaceutical Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 55. Indaco Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 56. InterMune, Inc. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 57. Bristol Myers Squibb Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 58. SHIONOGI & CO., Ltd. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2024-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries